ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals strong financial performance with a 46% increase in net sales, driven by DAYBUE and NUPLAZID. Despite lowered guidance for DAYBUE, optimistic guidance and strategic initiatives like DTC campaigns and pipeline advancements are highlighted. The Q&A section indicates confidence in future growth and addresses operational strategies. The lack of share buybacks or dividends is offset by robust cash flow. Considering the market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
Key Financial Performance
Total Net Sales $242 million, up 46% year-over-year due to strong performance from DAYBUE and NUPLAZID.
DAYBUE Net Product Sales $84.6 million, up from $23.2 million year-over-year, reflecting a recovery in active patients and a sequential increase of 11%.
NUPLAZID Net Product Sales $157.4 million, up 11% year-over-year, driven by stabilization in the Parkinson's disease psychosis market and effective real-world evidence studies.
R&D Expenses $76.2 million, up from $58.8 million year-over-year, primarily due to increased costs for ACP-101, ACP-204, and early-stage programs.
SG&A Expenses $117.1 million, up from $96 million year-over-year, mainly due to upfront costs related to a new consumer activation program and increased marketing costs.
Cash Balance $500.9 million, an increase of $30.4 million from the first quarter, reflecting strong cash flow.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
DAYBUE Net Product Sales: DAYBUE net product sales were $84.6 million, up 11% sequentially, with 900 active patients on therapy.
NUPLAZID Net Product Sales: NUPLAZID net product sales were $157.4 million, up 11% year-over-year.
Sales Guidance for DAYBUE: Guidance for DAYBUE net sales is lowered to $340 to $370 million.
Sales Guidance for NUPLAZID: Guidance for NUPLAZID net sales is increased to $590 to $610 million.
Market Awareness Campaigns: Initiating a targeted campaign to raise awareness of hallucinations and delusions in Parkinson's disease.
Expansion into International Markets: Submissions for DAYBUE in Canada and the EU, with plans for Japan.
Cash Position: ACADIA has over $500 million in cash with no debt.
Operational Efficiency: 46% year-over-year revenue growth driven by strong commercial franchises.
Pipeline Development: Advancing Phase 3 program for Prader-Willi syndrome and Phase 2-Phase 3 program in Alzheimer's disease psychosis.
Leadership Change: Elizabeth Thompson appointed as Executive Vice President, Head of Research and Development.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Competitive Pressures: Despite strong performance, the company faces competitive pressures in the Parkinson's disease market, particularly with the need to raise awareness of hallucinations and delusions associated with the disease, which has significantly declined during the pandemic.
Regulatory Issues: Regulatory challenges exist with the EU not agreeing to a master protocol for ACP-204, limiting enrollment at sites in that geography to Phase 2 only.
Supply Chain Challenges: The company has not explicitly mentioned supply chain challenges, but the need for effective communication and education to healthcare providers indicates potential operational hurdles in reaching broader audiences.
Economic Factors: The company is navigating a post-pandemic market where awareness of treatment options has decreased, impacting patient engagement and treatment initiation.
Financial Guidance: The company has lowered its guidance for DAYBUE net sales due to slower-than-expected growth in new patient starts, indicating potential revenue risks.
Market Awareness: There is a significant gap in awareness of NUPLAZID as a treatment option, with only 15% awareness among patients and caregivers, which could hinder patient access to necessary treatments.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
DAYBUE Guidance: Lowered guidance range for DAYBUE net sales for the year to $340 to $370 million.
NUPLAZID Guidance: Increased annual sales guidance for NUPLAZID in 2024 from $560-$590 million to a new range of $590-$610 million.
Commercial Initiatives: Initiating a targeted campaign to raise awareness of hallucinations and delusions in Parkinson's disease.
Pipeline Development: Advancing Phase 3 program for Prader-Willi syndrome and Phase 2-Phase 3 program in Alzheimer's disease psychosis.
Cash Position: Over $500 million in cash with no debt, providing confidence for future growth.
Total Revenue Guidance: Total revenue guidance updated to $930 to $980 million for the year.
R&D Expenses Guidance: Narrowed R&D expenses guidance to $305 to $350 million.
SG&A Expenses Guidance: Narrowed SG&A expenses guidance to $465 to $480 million.
Cash Guidance: Updated cash guidance range to $575 to $625 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Shareholder Return Plan: ACADIA Pharmaceuticals has not announced any share buyback program or dividend program during the Q2 2024 earnings call. The focus remains on funding growth through operational cash flow and advancing pipeline programs.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the difference in discontinuation and new start rates between community and COE?
A:Discontinuation rates are steady between COEs and non-COEs, with two-thirds of new prescriptions coming from COEs. The majority of prescriptions are expected to come from non-COEs over time.
Q:How does dose titration factor into the treatment?
A:Physicians can start at a lower dose and titrate up, which is being encouraged to help patients stay on therapy.
Q:What gives you confidence in your DAYBUE guidance?
A:Tracking towards the lower half of revised guidance, but initiatives and new data could help increase metrics.
Q:Can you clarify the Phase 2 and Phase 3 study readouts?
A:Phase 2 data will be released while Phase 3 is still enrolling, which is expected to spur enrollment.
Q:What is the impact of summer months on drug holidays and restarts?
A:Summer shows typical patient cycling, but COEs are operating at the same cadence. Expect new patient starts to progress as families return from vacations.
Q:Can you break down the 70% of diagnosed patients not on DAYBUE?
A:The highest penetration is in the 2-20 year age range, with physicians currently treating about 40% of their patients.
Q:What are the puts and pulls for NUPLAZID guidance?
A:Tracking around the midpoint of guidance, with outperformance expected from new patient starts and DTC campaign benefits.
Q:What is your confidence in ACP-101 for Prader-Willi syndrome?
A:Confidence comes from Phase 2 data showing significant reduction in hyperphagia.
Q:What is the impact of community engagement on discontinuations?
A:Ongoing efforts in GI management are starting to show benefits in active patients and reduced discontinuations.
Q:Do you have data on long-term patients on DAYBUE?
A:Some patients are on DAYBUE for over two years, with persistency rates above 50%.
Q:What are your expectations for DTC ROI for NUPLAZID?
A:Expect positive ROI based on previous campaigns, with a fertile environment for investment.
Q:What were the gross to net differences for DAYBUE from Q1 to Q2?
A:7% volume growth and 4% net benefit from price increase.
Q:What is your current prescriber base number?
A:Over 700 unique prescribers, with a focus on increasing prescriptions outside of COEs.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific percentage of patients who have stopped taking DAYBUE and have not restarted, as well as the exact breakdown of the 70% of diagnosed patients who have not initiated treatment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Acadia
COEs
DTC campaign
EU
Executive Vice
GI
LOTUS
PDP
President Head
Research Development
Today
awareness hallucination
body
center excellence
condition
confidence
core
course
field
foundation
gap
hallucination delusion
leader
manufacturer phase
market research
master protocol
patient start
percent
percentage
practice
price
provider
site
start rate
summer
term treatment
titration
view
ACAD Transcript
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q1 2025 Earnings Call Transcript
Unknown5-8
The earnings call summary presents a mixed picture: strong revenue growth and optimistic guidance, particularly for NUPLAZID, contrast with increased R&D and SG&A expenses. The absence of a share repurchase program and unresolved regulatory and competitive challenges add uncertainty. The Q&A section reveals confidence in future pricing and product success, but also highlights risks in regulatory approval and market competition. Given the market cap of approximately $2.7 billion, the overall sentiment suggests a neutral stock price movement in the near term.
Earnings call transcript: Acadia Pharmaceuticals beats Q1 2025 forecasts
Unknown5-7
The earnings call summary presents a mixed picture. Financial performance shows positive revenue growth but increased expenses. The Q&A highlights potential risks, such as regulatory and competitive pressures, and management's lack of clarity on certain issues. Despite the optimistic guidance and strong revenue growth, the absence of shareholder return plans and increased R&D expenses temper enthusiasm. Given the market cap, the stock is likely to remain stable, resulting in a neutral prediction.
ACADIA Pharmaceuticals Inc. (ACAD) Q3 2024 Earnings Conference Call Transcript
Positive11-7
The earnings call summary indicates strong financial performance with significant year-over-year sales growth for both DAYBUE and NUPLAZID. The company is in a strong financial position with a substantial cash balance and no debt, which supports future growth and potential shareholder returns. Although there is a lowered guidance for DAYBUE, the increased guidance for NUPLAZID and the sale of a priority review voucher enhance the positive sentiment. The Q&A section reveals some uncertainties, but overall, the financial metrics and strategic initiatives suggest a positive stock price movement.
ACADIA Pharmaceuticals Inc. (ACAD) Q2 2024 Earnings Call Transcript
Positive8-7
The earnings call reveals strong financial performance with a 46% increase in net sales, driven by DAYBUE and NUPLAZID. Despite lowered guidance for DAYBUE, optimistic guidance and strategic initiatives like DTC campaigns and pipeline advancements are highlighted. The Q&A section indicates confidence in future growth and addresses operational strategies. The lack of share buybacks or dividends is offset by robust cash flow. Considering the market cap, the stock is likely to experience a positive movement of 2% to 8% over the next two weeks.
ACAD Slides
ACAD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
